Open access · OA
via Europe PMC
A Systematic Review on Disease-Modifying Therapies in Parkinsonian Disorders.
Eijsvogel PPNM, Smits LMG, Kremer PHC, Groeneveld GJ.
Clinical pharmacology and therapeutics · 2026
Abstract
Parkinsonian disorders, including Parkinson's disease, Lewy body dementia, multiple system atrophy, and progressive supranuclear palsy, are progressive neurodegenerative conditions with no treatment options to slow disease progression. This systematic review provides an overview of evidence of disease-modifying therapies that have been evaluated in clinical studies across these disorders, based on a comprehensive literature search up to May 2025. Eligible studies included clinical trials investigating pharmacological interventions aimed at slowing disease progression. Most clinical development has focused on Parkinson's disease, with limited progress in other Parkinsonian disorders. Therapies targeting alpha-synuclein, such as monoclonal antibodies and small molecules, have shown target engagement but limited clinical efficacy. Glucocerebrosidase-enhancing agents, particularly ambroxol, demonstrated promising biomarker and clinical signals in early-phase trials. Glucagon-like peptide-1 receptor agonists and kinase inhibitors have yielded mixed results, with some agents progressing to phase 3 trials. Neurotrophic factors, cell survival and neuroprotective therapies, stem cell therapies, and anti-inflammatory agents remain largely investigational, with limited evidence of efficacy. Repurposed drugs, including memantine and riluzole, have shown preliminary signals of benefit, though confirmatory trials are lacking. Despite substantial research efforts, no disease-modifying therapy has been approved for any Parkinsonian disorder. The heterogeneity of disease mechanisms and the limitations of current clinical endpoints, such as the Unified Parkinson's Disease Rating Scale, underscore the need for biomarker-driven approaches and stratified trial designs. Future success will likely depend on improved patient selection, mechanistic targeting, and the integration of fluid and imaging biomarkers to demonstrate disease modification.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- Europe PMC
- DOI
- 10.1002/cpt.70315
- Canonical
- link ↗
- Fetched
- 2026-10-10 MST
Cite this
APA
PPNM, E., LMG, S., PHC, K., & GJ., G. (2026). A Systematic Review on Disease-Modifying Therapies in Parkinsonian Disorders. <em>Clinical pharmacology and therapeutics</em>. https://doi.org/10.1002/cpt.70315
Vancouver
PPNM E, LMG S, PHC K, GJ. G. A Systematic Review on Disease-Modifying Therapies in Parkinsonian Disorders. Clinical pharmacology and therapeutics. 2026. doi:10.1002/cpt.70315.
BibTeX
@article{eijsvogel2026ASyste,
title = {A Systematic Review on Disease-Modifying Therapies in Parkinsonian Disorders.},
author = {Eijsvogel PPNM and Smits LMG and Kremer PHC and Groeneveld GJ.},
journal = {Clinical pharmacology and therapeutics},
year = {2026},
doi = {10.1002/cpt.70315},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Innovation in Aging 2021
Open access · CC-BY
Operationalizing Healthspan as an Outcome for Clinical Trials in Geroscience
Biomaterials Research 2023
Open access · CC-BY
CRISPR/Cas9 assisted stem cell therapy in Parkinson's disease
The Journal of Prevention of Alzheimer s Disease 2023
Open access · CC-BY
Translating the Biology of Aging into New Therapeutics for Alzheimer's Disease: Senolytics
International journal of high school research 2025
Open access · OA
Disease Modification: Comparing Diverse Approaches to Alpha-Synuclein Targeting Therapies in Parkinson’s Disease
Kidney360 2023
Open access · CC-BY
Targeting Senescent Cells as Therapy for CKD
International Journal of Molecular Sciences 2025
Open access · CC-BY